Through high-resolution DNA analysis, the project identified key markers such as Single Nucleotide Polymorphisms (SNPs) linked to nutrient metabolism and physical performance. While the technology was in its early stages, Geneus identified data-driven solutions that moved well beyond the generic recommendations of the time. This clinical rigour provided the first "biological blueprint" for the group’s future ventures.

The legacy of Geneus forms the vital bridge between early genomic research and the sophisticated AI technology seen in Genelle today. While it was eventually phased out to allow for greater automation and regulatory compliance, it proved the viability of personalised products across diverse populations. It remains a foundational proof of concept and a testament to a decade of leadership in the biotech sector.